title: [Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases].
abstract: OBJECTIVE
  To evaluate the effect of atorvastatin (liprimar) on the laboratory values of inflammation and blood lipid composition in rheumatoid arthritis (RA) patients with no history of cardiovascular diseases (CVD). Subjects and methods. Fifty women with grade II RA activity according to DAS28 and radiologic (erosive) Stages I-III were examined; the patients were not former or current smokers; all were seropositive; their mean age was 50.2±9.9 years. All the patients with RA were divided into 2 groups: Group 1 took no atorvastatin and continued to receive standard previously prescribed therapy; Group 2 used atorvastatin in a dose of 20 mg. Lipidogram readings and the levels of Apo-A and Apo-B, neopterin, tumor necrosis factor-α, C-reactive protein, sP-selectin, sE-selectin, interleukin (IL)-6, IL-10, IL-12, and matrix metalloproteinases 3 and 9 were assessed.
  
  
  RESULTS
  The patients with RA show obvious blood lipid composition impairments. Incorporation of atorvastatin (liprimar) into combination therapy for RA not only causes a considerable reduction in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and apo-B levels, but also positively affects the inflammatory activity of the disease, by lowering the level of proinflammatory cytokines and increasing that of the anti-inflammatory cytokine IL-10.
  
  
  CONCLUSIONS
  The above changes may underlie the prevention of CVD complications in patients with RA.
authors.affiliation: Kemerovo State Medical Academy, Ministry of Health of Russia, Kemerovo, Russia.
authors.forename: S A
authors.initials: SA
authors.lastname: Smakotina
authors.affiliation: Kemerovo State Medical Academy, Ministry of Health of Russia, Kemerovo, Russia.
authors.forename: A R
authors.initials: AR
authors.lastname: Zelendinova
authors.affiliation: Kemerovo Regional Clinical Hospital, Ministry of Health of Russia, Kemerovo, Russia.
authors.forename: I N
authors.initials: IN
authors.lastname: Bondareva
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
authors.forename: S A
authors.initials: SA
authors.lastname: Berns
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000069059:Atorvastatin / Q000008:administration & dosage / Q000009:adverse effects; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood / Q000378:metabolism; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D008875:Middle Aged; D062072:Patient Acuity; D012217:Rheumatoid Factor / Q000097:blood; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; C508600:IL6 protein, human; D015850:Interleukin-6; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D012217:Rheumatoid Factor; D000069059:Atorvastatin; D019278:Matrix Metalloproteinase 3